TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00850642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo :~2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)
Study: NCT03166423
Drug: MU001 patches (Investigational)
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patches containing snail slime, calendula extract and propolis extract
Study: NCT01307839
Drug: placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours
Study: NCT01418963
Drug: RO5285119
Approvals — FDA: no, EMA: no, PMDA: no
Description: single and multiple ascending oral doses
Study: NCT01418963
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single and multiple oral doses
Study: NCT04751539
Drug: AND017 single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AND017 administrated as oral single-dose on Day 1 in Part A
Study: NCT04751539
Drug: AND017 multiple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AND017 administrated once daily from Day 1 to Day 10 in Part B
Study: NCT04751539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B
Study: NCT00788749
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets 25 mg/day
Study: NCT00788749
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets once daily
Study: NCT00679926
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four tablets of lopinavir/ritonavir and one tablet of tenofovir given once daily
Study: NCT00813566
Drug: 3'-deoxy-3'-[18F]fluorothymidine (FLT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain scan with a radiolabeled imaging agent for investigating cellular proliferation of tumors
Study: NCT00813566
Drug: [15O]-H2O
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain scan with imaging agent to determine tumor blood flow
Study: NCT00604123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray twice daily for 2 weeks.
Study: NCT02796118
Drug: ASP2151
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02796118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02963311
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Included maximally-tolerated statin therapy and/or other low density lipoprotein-cholesterol (LDL-C)-lowering therapies.
Study: NCT04167345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to VX-814 for oral administration.
Study: NCT01339663
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04435821
Drug: [18F]FTC-146
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be injected with 0.08 mCi/kg \[18F\]FTC-146. A whole-body PET/MRI scan will be performed after injection.
Study: NCT00823121
Drug: recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: gonadotropin stimulation with rFSH 150 IU/day from day 2 of menstrual cycle
Study: NCT00801359
Drug: BSSPlus solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03822832
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT05219461
Drug: Single dose of rhEGF 10mcg/ml or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
Study: NCT05219461
Drug: Single dose of rhEGF 50mcg/ml or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
Study: NCT05219461
Drug: Single dose of rhEGF 100mcg/ml or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
Study: NCT05219461
Drug: Multiple dose of rhEGF 10mcg/ml or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
Study: NCT05219461
Drug: Multiple dose of rhEGF 50mcg/ml or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
Study: NCT05219461
Drug: Multiple dose of rhEGF 100mcg/ml or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
Study: NCT02502773
Drug: Hydroxethyl starch
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02775474
Drug: Use of Intraoperative Intravenous Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The active control group will be given intravenous fentanyl at a fixed induction dose (6 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
Study: NCT00037102
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00058721
Drug: I-123-5-IA85380
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02618408
Drug: SPN-810 (18 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were randomized to receive SPN-810 low dose (18 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
Study: NCT02618408
Drug: SPN-810 (36 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were randomized to receive SPN-810 high dose (36 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
Study: NCT02618408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were randomized to receive Placebo twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
Study: NCT04650152
Drug: Tricor (fenofibrate), 145 mg, film-coated tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observational study without intervention. Fenofibrate is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
Study: NCT04588311
Drug: Epoetin Alfa 40000 UNT/ML
Normalized name: epoetin alfa 40000 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin alfa 40,000IU 1mL pre-filled syringe given as subcutaneous injection.
Study: NCT04870138
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alternative antibiotic treatment failure therapy: Azithromycin 2 g orally in a single dose after treatment failure with both cephalosporin and quinolone antibiotics.
Study: NCT01691924
Drug: PBF-509
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03284099
Drug: ACEi, ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: To take the ACEis or ARBs before bedtime instead of in the morning
Study: NCT02195453
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000mg/m² or Pemetrexed 500mg/m²IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection, 21 days for a cycle.~Placebo Capsule four granules t.i.d po.
Study: NCT00941148
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01186601
Drug: PET tracer (BAY94-9392)
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: A radioactive dose of 300 MBq of the study drug with a total quantity of \</= 0.1 mg will be administered as slow intravenous bolus injection over up to 60 seconds
Study: NCT00045539
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00045539
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03752463
Drug: DAOI-B group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAOI with B dose
Study: NCT03752463
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02500641
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 550 mg film coated tablets. In case of colchicine intolerance patients will be treated for at least 6 months with Naproxen 550 mg BID and Omeprazole (20-40 mg once daily), if indicated to be used.
Study: NCT02684708
Drug: cyclophosphamide, vincristine, prednisone, dacarbazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28-day chemotherapy cycle
Study: NCT01010100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg TID
Study: NCT02466542
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive regular general anesthesia
Study: NCT00543946
Drug: GAP-134
Normalized name: GAP JUNCTION ALPHA-3 PROTEIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-Hour IV infusion, SAD
Study: NCT00569621
Drug: physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration
Study: NCT01233830
Drug: AZD2423
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution
Study: NCT01233830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution
Study: NCT00214435
Drug: once daily minimum 3-drug regimen of anti-retroviral medications
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01584843
Drug: GSK1358820
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM injection of Botulinum Toxin Type A
Study: NCT04751084
Drug: Buscopan 20 milligrams/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: cases will be randomized to Buscopan group or Normal Saline group, injection will be given 5 minutes prior to embryo transfer
Study: NCT03744702
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive IV ascorbic acid.
Study: NCT03101982
Drug: HBO
Normalized name: Hib (HbOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygenation (HBO) is defined as breathing of 100% oxygen under elevated ambient pressure in a hyperbaric chamber. HBO is considered a pharmacological therapy.
Study: NCT00090181
Drug: MK0663, etoricoxib / Duration of Treatment: 4 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00090181
Drug: Comparator: diclofenac / Duration of Treatment: 4 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00563173
Drug: CHRONVAC-C®
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA vaccine, solution for injection, i.m. administration in combination with electroporation
Study: NCT01330927
Drug: VA106483
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral dose of placebo for 2 nights~Once daily oral dose of 0.5 mg VA106483 for 2 nights~Once daily oral dose of 1 mg VA106483 for 2 nights~Once daily oral dose of 2 mg VA106483 for 2 nights~Once daily oral dose of 4 mg VA106483 for 2 nights~Placebo: as above
Study: NCT03834012
Drug: Beclomethasone 800 µg per day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Drug: Beclomethasone 800 µg HFA per day
Study: NCT03834012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Drug: placebo
Study: NCT03834012
Drug: Beclomethasone 400 µg per day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Drug: Beclomethasone 400 µg HFA per day
Study: NCT03834012
Drug: Beclomethasone 640 µg per day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Drug: Beclomethasone 640 µg per day
Study: NCT01822275
Drug: Chemotherapy with Temodar.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
Study: NCT04298060
Drug: DAS181
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD (4.5mg/day), HD (9mg/day)
Study: NCT04298060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0mg/day
Study: NCT00902031
Drug: Sennoside + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.~Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days
Study: NCT00003592
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01826786
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to JNJ-42165279 will be orally administered once daily for 4 consecutive days.
Study: NCT02606214
Drug: TBA-354 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03516214
Drug: EGF816
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral treatment (once daily) with the 3rd generation EGFR inhibitor EGF816.
Study: NCT04430855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; Oral
Study: NCT01142479
Drug: Chinese herbal medicine decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml /Qd for 6 weeks(42 days)
Study: NCT00317252
Drug: Hold ACEI or ARB
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-96 hours post-catheterization (after creatinine measurement)
Study: NCT02240342
Drug: Bone marrow transplant into ovarian artery
Normalized name: Sus scrofa bone marrow preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow progenitors mobilized to peripheral blood, obtained by plasmapheresis and infused into the ovarian artery
Study: NCT04350320
Drug: Standard therapy for COVID-19 according to the stablished hospital protocols.
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard therapy for COVID-19 according to the stablished hospital protocols.
Study: NCT04557202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - control group
Study: NCT01580813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
Study: NCT00472836
Drug: CP-945,598
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of CP-945,598 in subjects with normal renal function.
Study: NCT00472836
Drug: CP-945,598
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of CP-945,598 in subjects with severe renal impairment.
Study: NCT00808964
Drug: NU172
Normalized name: NU172
Approvals — FDA: no, EMA: no, PMDA: no
Description: NU172 administered IV bolus followed by continuous infusion during CABG surgery
Study: NCT00390221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SC injection
Study: NCT00576615
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the day of the study infusion into the vein of a solution containing no drug, Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion. Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks.
Study: NCT00970944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice daily.
Study: NCT01412372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an inactive pill
Study: NCT00675064
Drug: GSK369796
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-malarial
Study: NCT00675064
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching GSK369796
Study: NCT03905564
Drug: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Tecnandina, S.A. TENSA).
Study: NCT03022175
Drug: SPR741
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD: Double-blind dosing will occur in cohorts 1 through 8. Six participants will receive single doses of SPR741. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD: The Safety Management Group will evaluate the safety and tolerability data obtained for the participants in Cohorts 1-5 to determine the appropriate dose level of intravenous q8h dosing of SPR741 to be utilized in the first cohort (Cohort 9) in the MAD. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 14 consecutive days.
Study: NCT03022175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride for injection. SAD: Two participants in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
Study: NCT05415657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equal volume of saline (0.9%) as placebo Q6M were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
Study: NCT02485301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose administrated intramuscular
Study: NCT00972738
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet orally once daily at bedtime for 2 weeks
Study: NCT02261844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 pill daily X 10 days
Study: NCT01708629
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo administered SC
Study: NCT01413516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill without any active medication
Study: NCT00532818
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin + Topotecan plus placebo
Study: NCT03426150
Drug: CPP-ACP
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The surfaces of specimens were pretreated with CPP-ACP for 3 min
Study: NCT02185651
Drug: Zavesca® Prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following baseline evaluation, Zavesca® prescription is given.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed.
Study: NCT02254161
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT02254161
Drug: BI 1181181 healthy elderly
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT02254161
Drug: BI 1181181 Healthy young
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT00006239
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02514850
Drug: Biochaperone Combo
Normalized name: NexGard Combo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of BioChaperone Combo
Study: NCT02514850
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of saline 0.9% solution
Study: NCT03426150
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: The surfaces of specimens were pretreated with deionized water for 3 min
Study: NCT01631305
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 mcg/kg/day
Study: NCT00060138
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01685411
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -3 and -2 (prior to transplantation): given as a 2 hour intravenous infusion with a high volume fluid flush and mesna per institutional guidelines. Dosing is based on actual body weight.
Study: NCT02833545
Drug: Steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of steroids (diprospan) intra articularly
Study: NCT00697164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline Admission, day 1, day 2 3 days
Study: NCT04390295
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, 24 weeks
Study: NCT04390295
Drug: SHR3824
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, 52 weeks
Study: NCT01850186
Drug: Stabilized kilnman trio
Normalized name: Simparica TRIO
Approvals — FDA: no, EMA: no, PMDA: no
Description: The stabilized kilnman trio will be prescribed for one month at inclusion (all over the face, one application per day), and on the half of the face not treated by laser at weeks 4, 8 and 12 (one application per day).
Study: NCT03996148
Drug: Remifentanil, Propofol, and Desflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Propofol - titratable; initial starting dose 75 mcg/kg/min Desflurane 0.5 MAC